research reports and media, page-3868

This is great to see, but this generic/biosimilar area is still fraught with risk, and Paradigm need a partner who can take on the Legal protection of Zilosul against attempts by biosimilar competitors to weasel their way into the market. Nothing exemplifies the need for legal vigilance better than the case of Arthropharm (Europe) failing to protect it's position. Have a look below...

https://www.irishtimes.com/business/manufacturing/court-dismisses-appeal-over-generic-drug-to-treat-osteoarthritis-in-dogs-1.4875055

Arthropharm (iPPS for veterinary use) didn't launch an appeal in time, when Europe's HRPA (Health Products Regulatory Authority) approved a biosimilar for treatment of animals (Chanelle Pharmaceuticals, who I note are mentioned in the research article Jcurve has shared). Arthropharm were asleep at the wheel, and now they have biosimilar competitor in Europe to deal with.

PAR simply cannot make mistakes like this. Hyper-vigilance will be required in this space, and I think it's one reason why our partner needs to be a real Big Pharma player, well-practiced in all the dark pharma arts.